{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-140321","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2021-11-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.190837+00:00","generated_at":"2026-06-28T07:15:56.372206+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Eloxx Phase 2 ELX-02 monotherapy shows 5.4 mmol/L sweat chloride reduction; advancing to Phase 3","bullets":["Statistically significant 5.4 mmol/L mean sweat chloride reduction at 1.5 mg/kg/day (p=0.022) in Class 1 CF patients with G542X mutation.","ELX-02 well tolerated; no treatment-related serious adverse events; most common mild injection site reactions.","Planning for Phase 3 clinical development initiated; 1.5 mg/kg/day dose selected for further study.","First patient dosed in Phase 2 combination arm with ivacaftor; topline data expected by H1 2022.","Evaluation of inhaled delivery of ELX-02 started; IND submission planned for H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-140321","json":"https://secwatch.observer/filing/0001104659-21-140321.json","markdown":"https://secwatch.observer/filing/0001104659-21-140321.md","text":"https://secwatch.observer/filing/0001104659-21-140321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921140321/0001104659-21-140321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465921140321/tm2133239d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T07:15:56.372206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}